Daewon Pharm (003220) — Cash Flow-to-Debt Ratio
Daewon Pharm (003220) has a Cash Flow-to-Debt Ratio of 0.09x as of December 2025, meaning its operating cash flow of ₩30.61 Billion could theoretically repay 0% of its total liabilities (₩339.07 Billion) in one year. Explore long-term investment intensity of Daewon Pharm to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Daewon Pharm Cash Flow-to-Debt Ratio (2011–2025)
Historical debt coverage capacity for Daewon Pharm across 15 annual periods. Also explore Daewon Pharm assets under control for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Daewon Pharm (2011–2025)
Year-by-year debt coverage analysis for Daewon Pharm. For market capitalisation and broader financial context, see Daewon Pharm stock valuation.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.12x | ₩42.31 Billion | ₩339.07 Billion | ▲ +24.2% |
| 2024 | 0.10x | ₩30.04 Billion | ₩298.81 Billion | ▼ -52.6% |
| 2023 | 0.21x | ₩51.73 Billion | ₩243.73 Billion | ▲ +30.4% |
| 2022 | 0.16x | ₩33.33 Billion | ₩204.78 Billion | ▲ +53.3% |
| 2021 | 0.11x | ₩22.41 Billion | ₩211.18 Billion | ▼ -47.9% |
| 2020 | 0.20x | ₩24.95 Billion | ₩122.44 Billion | ▼ -18.9% |
| 2019 | 0.25x | ₩30.97 Billion | ₩123.32 Billion | ▼ -42.1% |
| 2018 | 0.43x | ₩40.03 Billion | ₩92.24 Billion | ▲ +501.1% |
| 2017 | 0.07x | ₩4.27 Billion | ₩59.07 Billion | ▼ -81.7% |
| 2016 | 0.39x | ₩20.79 Billion | ₩52.67 Billion | ▼ -29.5% |
| 2015 | 0.56x | ₩25.82 Billion | ₩46.09 Billion | ▲ +48.0% |
| 2014 | 0.38x | ₩17.45 Billion | ₩46.11 Billion | ▲ +13.3% |
| 2013 | 0.33x | ₩12.32 Billion | ₩36.89 Billion | ▼ -17.4% |
| 2012 | 0.40x | ₩13.83 Billion | ₩34.20 Billion | ▼ -17.8% |
| 2011 | 0.49x | ₩17.93 Billion | ₩36.47 Billion | — |